Table 4 Comparisons of characteristics and examination findings between anti-MDA-5-positive survivors and non-survivors
Survivors | Non-survivors | p value | |
|---|---|---|---|
(n = 4) | (n = 6) | ||
Gender (male/female) | 2/2 | 4/2 | 1.00 |
Age | 58.5 (47.8–64.3) | 63.0 (59.3–64.5) | 0.519 |
Time | |||
from onset to first visit | 29.5 (26.0–50.3) | 11.0 (11.0–13.3) | 0.0666 |
from onset to treatment initiation | 68.5 (31.5–107) | 16.0 (12.8–23.0) | 0.0381 |
Symptoms and signs | |||
Gottron’s sign | 2 (50 %) | 5 (83 %) | 0.500 |
Heliotrope eruption | 2 (50 %) | 5 (83 %) | 0.500 |
V/shawl neck sign | 1 (25 %) | 4 (67 %) | 0.524 |
Mechanic’s hands | 0 | 2 (33 %) | 0.467 |
Palmar erythema | 0 | 2 (33 %) | 0.467 |
Myalgia | 2 (50 %) | 1 (17 %) | 0.500 |
Cough | 4 (100 %) | 1 (17 %) | 0.0480 |
Dyspnea on exertion | 3 (75 %) | 2 (33 %) | 0.524 |
Fever | 3 (75 %) | 6 (100 %) | 0.200 |
Laboratory data | |||
Aspartate aminotransferase | 55.5 (36.8–76.8) | 55.5 (41.0–110) | 0.762 |
γ-glutamyl transpeptidase | 53.5 (43.5–57.5) | 28.0 (23.0–110) | 0.914 |
Krebs von den Lungen-6 | 1135 (930–1190) | 524 (470–626) | 0.114 |
Surfactant protein D | 45.3 (23.7–75.8) | 32.5 (24.2–40.9) | 0.669 |
Bronchoalveolar lavage | |||
CD4+/CD8+ ratio | 3.52 (2.12–4.04) | 1.47 (1.20–2.19) | 0.857 |
HRCT findings | |||
Consolidation | 1 (25 %) | 0 | 0.400 |
Ground glass opacity | 0 | 5 (83 %) | 0.0480 |
Reticulation | 1 (25 %) | 0 | 1.00 |
Irregular linear opacity | 2 (50 %) | 1 (17 %) | 0.500 |